Related coverage linked through entity extraction aliases.
Feb 15, 2026
Multiple television personalities have openly discussed their use of GLP-1 medications for weight loss, with some experiencing facial changes known as "Ozempic face" characterized by volume loss and more pronounced features.
Feb 13, 2026
Vistagen reported fiscal Q3 2026 results with $61.8 million in cash as of December 31, 2025, while advancing its PALISADE-4 Phase 3 trial of fasedienol for social anxiety disorder and preparing an IND submission for refisolone in menopause symptoms.
Feb 13, 2026
The FDA removed black box warnings related to breast cancer, cardiovascular disease and dementia from six hormone replacement therapies for menopausal women, following a comprehensive review of scientific literature.
Feb 13, 2026
The FDA has approved labeling changes to six menopausal hormone therapy products, removing boxed warnings related to cardiovascular disease, breast cancer, and probable dementia that had been in place since 2003.
